Categories: NewsOptometrist

Dr. Parul Khator Becomes First Doctor In Georgia to Use the iTrack Advance Canaloplasty Device for Glaucoma

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Minimally invasive device reduces intraocular pressure for adults with open angle glaucoma

ATLANTA–(BUSINESS WIRE)–Georgia Eye Partners is proud to share that Dr. Parul Khator has become the first eye surgeon in Georgia to utilize the iTrack Advance Canaloplasty Device, a minimally invasive glaucoma surgical device (MIGS) used to reduce intraocular pressure (IOP) in adult patients with primary open-angle glaucoma. The device offers a more efficient glaucoma procedure for patients and surgeons, and can be used standalone or in combination with cataract surgery to help control a glaucoma patient’s eye pressure while lessening their medication burden.


“I am constantly looking for minimally invasive treatment options for my patients that can deliver good results with less risk,” said Dr. Parul Khator, Georgia Eye Partners ophthalmologist and glaucoma specialist. “I personally like the low inflammation profile of this procedure and the device provides me greater visibility and control during surgery.”

Glaucoma, a leading cause of blindness and visual impairment in the U.S., encompasses a group of diseases damaging the optic nerve due to increased eye pressure, potentially caused by infection, injury, blocked vessels, or inflammation. Early-stage glaucoma often lacks symptoms, but as it advances, patients might notice peripheral vision loss, sudden eye pain, headaches, blurred vision, or halos around lights.

First introduced into the U.S. market in 2008, canaloplasty is a stent-free, minimally invasive glaucoma surgery (MIGS) that works with patient physiology to reduce intraocular pressure in glaucoma patients.

Specifically, canaloplasty uses an approach akin to angioplasty to treat blockages in all parts of the eye’s drainage channel, referred to as the conventional outflow pathway – trabecular meshwork, Schlemm’s canal and collector channels – to improve the physiologic outflow of aqueous humor. This contrasts with other MIGS procedures, which mechanically alter the outflow of aqueous humor via a stent or tissue removal.

Georgia Eye Partners remains committed to serving patients throughout Greater Atlanta and Georgia by implementing the latest and greatest advanced glaucoma technologies and procedures.

About Georgia Eye Partners

Georgia Eye Partners is a group practice of ophthalmologists and optometrists committed to providing premier medical and surgical specialty eye care to patients in the Metro Atlanta and North Georgia region, with seven offices in Decatur, Downtown Decatur, Johns Creek, Northside, Emory Midtown, Woodstock, Snellville and North Brookhaven areas. Our services range from disease-specific medical exams to complex specialty surgical care and our outpatient surgery center features state-of-the-art equipment and accreditation from the American Association for Accreditation of Ambulatory Surgery Facilities (AAAASF). To learn more about us, visit us at: www.gaeyepartners.com.

About Nova Eye Medical

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include the iTrack™ portfolio of canaloplasty devices for the treatment of glaucoma. The Company also manufactures and sells the proprietary Molteno3® glaucoma drainage device for the treatment of severe or complex glaucoma. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by sales offices in Adelaide, Australia and Berlin, Germany, and a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

Contacts

Jules Lydon

(404) 383-0868

julianna.lydon@eyesouthpartners.com

Staff

Recent Posts

FinThrive Introduces Agentic AI at HFMA 2025 to Help Customers Transform Healthcare Revenue Cycle Management Performance

Company to also highlight advancements in denials and underpayments management and speak to the measurable…

3 hours ago

FinThrive Debuts Denials and Underpayments Analyzer, a Unified Solution for Denials and Underpayments, at HFMA 2025

Next generation analyzer helps hospitals protect revenue before it's lost by delivering timely end-to-end visibility…

3 hours ago

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine

Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed mean weight reduction…

6 hours ago

Dr. Anosh Ahmed Advances Chicago Crypto Hub Project as Federal Support for Blockchain Grows

Dr. Anosh Ahmed repurposes West Side warehouse into blockchain innovation center, targeting 250+ jobs and…

6 hours ago

Dr. Anosh Ahmed Advances Chicago Crypto Hub Project Amid National Pro-Crypto Policy Shift

Dr. Anosh Ahmed converts vacant West Side warehouse into blockchain innovation hub, creating 250+ jobs…

6 hours ago

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits…

6 hours ago